Response rate | Galcanezumab 120 mg (N = 436) | Galcanezumab 240 mg (N = 428) | Placebo (N = 875) |
Episodic migraine | |||
Overall 6 months | 60.8% | 58.7% | 37.2% |
Odds ratio (95% CI) | 2.6 (2.2, 3.1)* | 2.4 (2.0, 2.8)* | |
Month 1, % | 50.9% | 47.2% | 23.8% |
Odds ratio (95% CI) | 3.3 (2.6, 4.2)* | 2.9 (2.2, 3.7)* | |
Month 6, % | 65.7% | 63.2% | 44.3% |
Odds ratio (95% CI) | 2.4 (1.9, 3.1)* | 2.2 (1.7, 2.8)* | |
Chronic migraine | Galcanezumab 120 mg (N = 273) | Galcanezumab 240 mg (N = 274) | Placebo (N = 538) |
Overall 3 months | 27.6% | 27.5% | 15.4% |
Odds ratio (95% CI) | 2.1 (1.6, 2.8)* | 2.1 (1.6, 2.8)* | |
Month 1, % | 23.7% | 21.2% | 9.9% |
Odds ratio (95% CI) | 2.8 (1.9, 4.2)* | 2.5 (1.7, 3.6)* | |
Month 3, % | 31.9% | 34.0% | 22.4% |
Odds ratio (95% CI) | 1.6 (1.2, 2.3)† | 1.8 (1.3, 2.5)* |